Nivolumab is an immunotherapy drug that has been described as a potential "game-changer" in cancer as presented at the European Cancer Congress. Researchers found out that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.
09 Aug '24 16:35PM